The maintenance of a Buy rating and a $16 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence in investors about Inozyme Pharma's future prospects. This endorsement could lead to increased investor interest and potentially a positive impact on the stock price in the short term.